Adaptive Biotechnologies Corporation (ADPT) Plunges 10.15%

Adaptive Biotechnologies Corporation (ADPT) Plunges 10.15%

Adaptive Biotechnologies Corporation (ADPT) had a rough trading day for Monday October 21 as shares tumbled 10.15%, or a loss of $-2.9699 per share, to close at $26.30. After opening the day at $28.39, shares of Adaptive Biotechnologies Corporation traded as high as $29.41 and as low as $25.70. Volume was 745,877 shares over 6,563 trades, against an average daily volume of n/a shares and a total float of 124.29 million.

As a result of the decline, Adaptive Biotechnologies Corporation now has a market cap of $3.27 billion. In the last year, shares of Adaptive Biotechnologies Corporation have traded between a range of $55.12 and $26.63, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Adaptive Biotechnologies Corp is a a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Adaptive Biotechnologies Corporation is based out of Seattle, WA and has some 346 employees. Its CEO is Chad Robins.

Adaptive Biotechnologies Corporation is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!